Strata Critical Medical, Inc. (SRTAW) — SEC Filings
Strata Critical Medical, Inc. (SRTAW) — 28 SEC filings. Latest: 8-K (Dec 3, 2025). Includes 7 8-K, 7 SC 13G/A, 6 10-Q.
View Strata Critical Medical, Inc. on SEC EDGAR
Overview
Strata Critical Medical, Inc. (SRTAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Strata Critical Medical, Inc. filed an 8-K on December 3, 2025, reporting on events as of December 2, 2025. The filing indicates changes in directors or officers, potential new appointments, and details on compensatory arrangements. It also includes Regulation FD disclosures and financial statements
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Strata Critical Medical, Inc. is neutral.
Filing Type Overview
Strata Critical Medical, Inc. (SRTAW) has filed 7 8-K, 3 8-K/A, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of SRTAW's 21 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $49,298,000 |
| Net Income | $57,416,000 |
| Cash Position | $22,753,000 |
| Total Assets | $335,078,000 |
Key Executives
- Robert S. Wiesenthal
- Melissa M. Tomkiel
- William A. Heyburn
Industry Context
Strata Critical Medical operates within the healthcare services sector, which is characterized by increasing demand for specialized medical services and ongoing consolidation. The company's strategic shift towards core medical services, exemplified by the acquisition of Keystone Perfusion Services, aligns with industry trends focused on efficiency and specialized care delivery. However, the sector also faces pressures from regulatory changes and reimbursement rate fluctuations.
Top Tags
amendment (6) · financials (4) · 10-Q (4) · 8-K (3) · Blade Air Mobility (3) · institutional-ownership (3) · corporate-governance (2) · filing (2) · acquisition (2) · financial-statements (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $57.416M | Swung from a $1.954M net loss in Q3 2024 to a profit in Q3 2025, largely due to discontinued operations. |
| Net Income from Discontinued Operations | $67.073M | Primary driver of the overall net income for Q3 2025, from the sale of the Passenger business. |
| Revenue from Continuing Operations | $49.298M | Increased 36.7% from $36.062M in Q3 2024, indicating growth in core medical services. |
| Loss from Continuing Operations Before Income Taxes | ($9.657M) | Worsened from ($5.627M) in Q3 2024, highlighting ongoing challenges in core profitability. |
| Realized Loss from Short-Term Investments | $5.195M | Contributed to the increased loss from continuing operations. |
| Accounts Receivable | $37.538M | Nearly doubled from $19.822M at December 31, 2024, suggesting significant sales growth or potential collection issues. |
| Goodwill | $84.607M | Increased significantly from $15.540M at December 31, 2024, reflecting recent acquisitions like Keystone Perfusion Services. |
| Intangible Assets, net | $49.754M | Rose substantially from $7.964M at December 31, 2024, also due to acquisitions. |
| Common Shares Issued | 86,050,917 | Increased from 79,419,028 at December 31, 2024, partly due to shares issued in acquisition. |
| Major Customer Revenue Concentration | 13% | One customer accounted for 13% of revenue for the three and nine months ended September 30, 2025. |
| Net Loss (Q2 2025) | $11.7M | Increased from $9.5M in Q2 2024, indicating widening losses. |
| Net Loss (YTD 2025) | $23.5M | Increased from $19.0M in YTD 2024, showing a growing deficit. |
| Accumulated Deficit | $200.5M | Increased from $177.0M at year-end 2024, highlighting persistent unprofitability. |
| Common Shares Outstanding | 69.45M | Stable as of June 30, 2025, compared to December 31, 2024. |
| Additional Paid-In Capital | $320.0M | Slight increase from $319.8M at year-end 2024, reflecting minor equity adjustments. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Strata Critical Medical, Inc. (SRTAW)?
Strata Critical Medical, Inc. has 28 recent SEC filings from Jan 2024 to Dec 2025, including 7 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SRTAW filings?
Across 28 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Strata Critical Medical, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Strata Critical Medical, Inc. (SRTAW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Strata Critical Medical, Inc.?
Key financial highlights from Strata Critical Medical, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SRTAW?
The investment thesis for SRTAW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Strata Critical Medical, Inc.?
Key executives identified across Strata Critical Medical, Inc.'s filings include Robert S. Wiesenthal, Melissa M. Tomkiel, William A. Heyburn.
What are the main risk factors for Strata Critical Medical, Inc. stock?
Of SRTAW's 21 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Strata Critical Medical, Inc.?
Forward guidance and predictions for Strata Critical Medical, Inc. are extracted from SEC filings as they are enriched.